We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.68%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$223M
AUM Growth
-$41.4M
(-16%)
Cap. Flow
-$38.1M
Cap. Flow
% of AUM
-17.06%
Top 10 Holdings %
Top 10 Hldgs %
11%
Holding
420
New
44
Increased
50
Reduced
231
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Mosaic Company
MOS
|
+$2.06M |
| 2 |
Petrobras
PBR
|
+$2M |
| 3 |
Vale
VALE
|
+$1.96M |
| 4 |
Cheniere Energy
CQP
|
+$1.94M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boise Cascade
BCC
|
+$2.62M |
| 2 |
Extra Space Storage
EXR
|
+$2.49M |
| 3 |
Canadian Natural Resources
CNQ
|
+$2.46M |
| 4 |
Imperial Oil
IMO
|
+$2.45M |
| 5 |
Avient
AVNT
|
+$2.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 20.16% |
| 2 | Real Estate | 20.02% |
| 3 | Healthcare | 16.51% |
| 4 | Energy | 10.55% |
| 5 | Utilities | 10.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Aldeyra Therapeutics
ALDX
$97.1M
| $102K | 0.05% |
22,945
-1,353
| -6% | -$5.39K |
|
302
uniQure
QURE
$2.75B
| $100K | 0.04% |
5,513
-328
| -6% | -$5.73K |
|
303
Zentalis Pharmaceuticals
ZNTL
$332M
| $100K | 0.04% |
2,169
-136
| -6% | -$7.34K |
|
304
Allogene Therapeutics
ALLO
$625M
| $99K | 0.04% |
10,848
-639
| -6% | -$6.66K |
|
305
Erasca
ERAS
$6.15B
| $99K | 0.04% |
11,532
-681
| -6% | -$7.89K |
|
306
Intellia Therapeutics
NTLA
$1.51B
| $98K | 0.04% |
1,353
-72
| -5% | -$6.1K |
|
307
Viking Therapeutics
VKTX
$3.88B
| $98K | 0.04% |
32,708
-1,945
| -6% | -$6.98K |
|
308
Invivyd
IVVD
$160M
| $97K | 0.04% |
21,355
-1,270
| -6% | -$7.77K |
|
309
Verastem
VSTM
$528M
| $97K | 0.04% |
5,744
-340
| -6% | -$5.85K |
|
310
Replimune Group
REPL
$454M
| $96K | 0.04% |
5,647
-339
| -6% | -$6.4K |
|
311
TG Therapeutics
TGTX
$8.19B
| $95K | 0.04% |
9,941
-595
| -6% | -$6.89K |
|
312
Instil Bio
TIL
$49M
| $95K | 0.04% |
441
-25
| -5% | -$5.84K |
|
313
Inovio Pharmaceuticals
INO
$85.6M
| $94K | 0.04% |
2,187
-129
| -6% | -$5.81K |
|
314
Precigen
PGEN
$1.94B
| $93K | 0.04% |
43,928
-2,603
| -6% | -$6.34K |
|
315
Atara Biotherapeutics
ATRA
$72.6M
| $92K | 0.04% |
395
-23
| -6% | -$7.32K |
|
316
Roivant Sciences
ROIV
$23.6B
| $92K | 0.04% |
18,546
-1,102
| -6% | -$7.27K |
|
|
MRTX
317
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $92K | 0.04% |
1,114
-69
| -6% | -$7.06K |
|
|
ADAP
318
DELISTED
Adaptimmune Therapeutics
ADAP
| $91K | 0.04% |
44,300
-2,631
| -6% | -$7.1K |
|
319
Prelude Therapeutics
PRLD
$375M
| $90K | 0.04% |
13,048
-767
| -6% | -$7.01K |
|
|
DAWN
320
DELISTED
Day One Biopharmaceuticals
DAWN
| $88K | 0.04% |
8,886
-527
| -6% | -$6.96K |
|
321
Sutro Biopharma
STRO
$386M
| $88K | 0.04% |
1,067
-64
| -6% | -$6.09K |
|
|
INBX
322
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $88K | 0.04% |
3,968
-232
| -6% | -$5.92K |
|
323
Praxis Precision Medicines
PRAX
$8.11B
| $87K | 0.04% |
568
-34
| -6% | -$6.98K |
|
324
Vir Biotechnology
VIR
$1.46B
| $87K | 0.04% |
3,374
-194
| -5% | -$5.75K |
|
|
AMTI
325
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $87K | 0.04% |
11,621
-692
| -6% | -$5.73K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, Virtus ETF Advisers held 420 positions worth $223M, down 16% from $265M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers withdrew a net $38.1M in Q1 2022, closing 47 positions and reducing 231 holdings. Its most notable exit was Boise Cascade, an estimated $2.62M position sold in full.
By sector, the portfolio is most concentrated in Materials at 20% of assets, up from 14% a quarter earlier, followed by Real Estate and Healthcare.
Against the trend, Virtus ETF Advisers opened a new position in The Mosaic Company worth $2.75M.
- Virtus ETF Advisers's largest Q1 2022 buy was The Mosaic Company: 41,283 shares worth $2.75M.
- Virtus ETF Advisers added most to Agnico Eagle Mines in Q1 2022, an estimated $1.28M increase.
- Virtus ETF Advisers's biggest Q1 2022 reduction was Gold Fields, cutting an estimated $1.09M.
- Virtus ETF Advisers fully exited Boise Cascade in Q1 2022, selling an estimated $2.62M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $223M portfolio in Q1 2022.
- Virtus ETF Advisers opened 44 new positions and closed 47 in Q1 2022.
- Virtus ETF Advisers's portfolio value fell 16% quarter-over-quarter to $223M.
Based on Virtus ETF Advisers's 13F filing for Q1 2022, filed 16 May 2022.